{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:42:17Z","timestamp":1789792937158,"version":"4.0.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.drudis.2022.02.024","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:54:00Z","timestamp":1646222040000},"page":"1545-1553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit"],"prefix":"10.1016","volume":"27","author":[{"given":"Wenteng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.02.024_b0005","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0140-6736(19)30148-5","article-title":"Influenza","volume":"393","author":"Barnett","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2022.02.024_b0010","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.335.6073.1155","article-title":"Surprising twist in debate over lab-made H5N1","volume":"335","author":"Cohen","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.drudis.2022.02.024_b0015","doi-asserted-by":"crossref","unstructured":"S. Herfst, J.A. Schrauwen, M. Linster, S. Chutinimitkul, E. deWit, V.J. Munster, E.M. Sorrell, T.M. Bestebroer, D.F. Burke, D.J. Smith, G.F. Rimmelzwaan, A.D.M.E. Osterhaus, R.A.M. Fouchier. Airborne transmission of influenza A\/H5N1 virus between ferrets. Science 336 (2012) 1524\u20131541.","DOI":"10.1126\/science.1213362"},{"key":"10.1016\/j.drudis.2022.02.024_b0020","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nri2054","article-title":"Scientific barriers to develop vaccines against avian influenza viruses","volume":"7","author":"Subbarao","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2022.02.024_b0025","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00018-014-1615-2","article-title":"Antiviral strategies against influenza virus: towards new therapeutic approaches","volume":"71","author":"Loregian","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.drudis.2022.02.024_b0030","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/j.1460-2075.1985.tb04038.x","article-title":"The molecular basis of the specific anti-influenza action of amantadine","volume":"4","author":"Hay","year":"1985","journal-title":"EMBO J"},{"key":"10.1016\/j.drudis.2022.02.024_b0035","doi-asserted-by":"crossref","first-page":"104780","DOI":"10.1016\/j.antiviral.2020.104780","article-title":"Put a cork in it: plugging the M2 viral ion channel to sink influenza","volume":"178","author":"Jalily","year":"2020","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.024_b0040","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1586\/14787210.4.5.795","article-title":"Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors","volume":"4","author":"Hurt","year":"2006","journal-title":"Expert Rev Anti-infect Ther"},{"key":"10.1016\/j.drudis.2022.02.024_b0045","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase inhibitors for influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2022.02.024_b0050","doi-asserted-by":"crossref","first-page":"505","DOI":"10.18388\/abp.2014_1871","article-title":"Influenza viruses resistant to neuraminidase inhibitors","volume":"61","author":"Nitsch-Osuch","year":"2014","journal-title":"Acta Biochim Pol"},{"key":"10.1016\/j.drudis.2022.02.024_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(00)00103-0","article-title":"Resistance of influenza viruses to neuraminidase inhibitors-a review","volume":"47","author":"Mckimm-Breschkin","year":"2000","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.024_b0060","doi-asserted-by":"crossref","first-page":"e00224","DOI":"10.1128\/CMR.00224-20","article-title":"Understanding the impact of resistance to influenza antivirals","volume":"34","author":"Holmes","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.drudis.2022.02.024_b0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.drudis.2022.02.024_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.20096","article-title":"Anti-influenza virus agents: synthesis and mode of action","volume":"28","author":"Lagoja","year":"2008","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2022.02.024_b0075","series-title":"Fields Virology","article-title":"Orthomyxoviridae: the viruses and their replication","author":"Lamb","year":"1996"},{"key":"10.1016\/j.drudis.2022.02.024_b0080","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0092-8674(81)90449-9","article-title":"A unique cap (m7G pppXm)-dependent influenza virion endonucleases cleaves capped RNAs to generate the primers that initiate viral RNA transcription","volume":"23","author":"Plotch","year":"1981","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2022.02.024_b0085","doi-asserted-by":"crossref","first-page":"28411","DOI":"10.1074\/jbc.R110.117531","article-title":"Influenza A virus polymerase: structure insights into replication and host adaptation mechanisms","volume":"285","author":"Boivin","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0090","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nsmb.1421","article-title":"The structural basis for cap binding by influenza virus polymerase subunit PB2","volume":"15","author":"Guilligay","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.drudis.2022.02.024_b0095","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature07745","article-title":"The cap-snatching endonucleases of influenza virus polymerase resides in the PA subunit","volume":"458","author":"Dias","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.02.024_b0100","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/nature07120","article-title":"Crystal structure of the polymerase PA(C)-PB1(N) complex from an avian influenza H5N1 virus","volume":"454","author":"He","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.02.024_b0105","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.drudis.2022.02.024_b0110","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1021\/acsinfecdis.7b00265","article-title":"Inhibitors of influenza A virus polymerase","volume":"4","author":"Yuan","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.024_b0115","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.024_b0120","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.2174\/0929867325666180706112940","article-title":"Focusing on the influenza virus polymerase complex: recent progress in drug discovery and assay development","volume":"26","author":"Zhang","year":"2019","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0125","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/med.21401","article-title":"The influenza virus polymerase complex: an update on its structure, functions, and significance for antiviral drug design","volume":"36","author":"Stevaert","year":"2016","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2022.02.024_b0130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.drudis.2018.01.028","article-title":"Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics","volume":"23","author":"Zhou","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2022.02.024_b0135","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1021\/acsinfecdis.7b00265","article-title":"Inhibitors of influenza A virus polymerase","volume":"4","author":"Yuan","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.024_b0140","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.024_b0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/irv.12446","article-title":"Influenza antivirals currently in late-phase clinical trial","volume":"11","author":"Koszalka","year":"2017","journal-title":"Influenza Other Respi Viruses"},{"key":"10.1016\/j.drudis.2022.02.024_b0150","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1021\/acs.jmedchem.6b01227","article-title":"Inhibitors of influenza virus polymerase acidic (PA) endonuclease: contemporary developments and perspectives","volume":"60","author":"Ju","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0155","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.1021\/acs.jmedchem.8b01363","article-title":"Structure-activity relationships in metal-binding pharmacophores for influenza endonuclease","volume":"61","author":"Credille","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0160","doi-asserted-by":"crossref","first-page":"7699","DOI":"10.1021\/acs.jmedchem.5b01474","article-title":"Polymerase acidic protein-basic protein 1 (PA-PB1) protein-protein interaction as a target for next-generation anti-influenza therapeutics","volume":"59","author":"Massari","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0165","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00552","article-title":"Inhibition of influenza virus polymerase by interfering with its protein-protein interactions","volume":"6","author":"Massari","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.024_b0170","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/acschembio.9b00552","article-title":"Discovery of influenza polymerase PA-PB1 interaction inhibitors using an in vitro split-luciferase complementation-based assay","volume":"15","author":"Zhang","year":"2020","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2022.02.024_b0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2016.11.005","article-title":"Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface","volume":"137","author":"Yuan","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.024_b0180","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1038\/s41598-018-22875-9","article-title":"Exploring Ugi-Azide four component reaction products for broad-spectrum influenza antivirals with a high genetic barrier to drug resistance","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.02.024_b0185","doi-asserted-by":"crossref","first-page":"19151","DOI":"10.1073\/pnas.1013592107","article-title":"High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity","volume":"107","author":"Su","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.02.024_b0190","doi-asserted-by":"crossref","first-page":"e1002668","DOI":"10.1371\/journal.ppat.1002668","article-title":"A novel small molecule inhibitor of influenza A viruses that targets polymerase function and indirectly induces interferon","volume":"8","author":"Ortigoza","year":"2012","journal-title":"Plos Pathog"},{"key":"10.1016\/j.drudis.2022.02.024_b0195","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","article-title":"In vitro and in vivo activities of anti-influenza virus compound T-705","volume":"46","author":"Furuta","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.024_b0200","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infection","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.024_b0205","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.024_b0210","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.024_b0215","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil Investigators Group. Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2022.02.024_b0220","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.024_b0225","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1073\/pnas.0909603107","article-title":"T-705(favipiravir) activity against lethal H5N1 influenza A viruses","volume":"107","author":"Kiso","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2022.02.024_b0230","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/cid\/ciz908","article-title":"Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes","volume":"71","author":"Hirotsu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.024_b0235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/dmp.2014.151","article-title":"Favipiravir: a new medication for the Ebola virus disease pandemic","volume":"9","author":"Nagata","year":"2015","journal-title":"Disaster Med Public Health Prep"},{"key":"10.1016\/j.drudis.2022.02.024_b0240","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.024_b0245","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/13543784.2019.1606210","article-title":"Investigational antiviral therapies for the treatment of influenza","volume":"28","author":"Yang","year":"2019","journal-title":"Expert Opin Investing Drugs"},{"key":"10.1016\/j.drudis.2022.02.024_b0250","doi-asserted-by":"crossref","first-page":"8915","DOI":"10.1021\/jm401369y","article-title":"New 7-methylguanine derivatives targeting the influenza polymerase pb2 cap-binding domain","volume":"56","author":"St\u00e9phane","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0255","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.micinf.2020.05.021","article-title":"Dihydromyricetin is a new inhibitor of influenza polymerase PB2 subunit and influenza-induced inflammation","volume":"22","author":"Tian","year":"2020","journal-title":"Microbes Infect"},{"key":"10.1016\/j.drudis.2022.02.024_b0260","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/cbdd.13740","article-title":"Methyl brevifolincarboxylate, a novel influenza virus PB2 inhibitor from Canarium Album (Lour.) Raeusch","volume":"96","author":"Chen","year":"2020","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.drudis.2022.02.024_b0265","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/jac\/dkw194","article-title":"A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication","volume":"71","author":"Yuan","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.drudis.2022.02.024_b0270","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/acs.molpharmaceut.8b00531","article-title":"A small-molecule compound has anti-influenza A virus activity by acting as a \u2018PB2 inhibitor\u2019","volume":"15","author":"Liu","year":"2018","journal-title":"Mol Pharmaceutics"},{"key":"10.1016\/j.drudis.2022.02.024_b0275","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2006.07.006","article-title":"A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals","volume":"73","author":"Noah","year":"2007","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2022.02.024_b0280","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0285","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.drudis.2022.02.024_b0290","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1248\/cpb.c17-00380","article-title":"7-Azaindole: a versatile scaffold for developing kinase inhibitors","volume":"66","author":"Irie","year":"2018","journal-title":"Chem Pharm Bull"},{"key":"10.1016\/j.drudis.2022.02.024_b0295","doi-asserted-by":"crossref","first-page":"19935","DOI":"10.3390\/molecules191219935","article-title":"The azaindole framework in the design of kinase inhibitors","volume":"19","author":"M\u00e9rour","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.02.024_b0300","doi-asserted-by":"crossref","first-page":"112506","DOI":"10.1016\/j.ejmech.2020.112506","article-title":"The importance of indole and azaindole scaffold in the development of antitumor agents","volume":"203","author":"Han","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0305","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.bmcl.2015.03.013","article-title":"Isosteric replacements of the carboxylic acid of drug candidate VX-787: effect of charge on antiviral potency and kinase activity of azaindole-based influenza PB2 inhibitors","volume":"25","author":"Boyd","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.02.024_b0310","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1021\/acsmedchemlett.6b00486","article-title":"Discovery of novel, orally bioavailable \u03b2-amino acid azaindol inhibitors of influenza PB2","volume":"8","author":"Farmer","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.02.024_b0315","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.bmcl.2019.04.042","article-title":"Discovery of 5-(5-fluoro-1H-pyrrolo [2,3-b] pyridin-3-yl) pyrazin-2(1H)-one derivatives as new potent PB2 inhibitors","volume":"29","author":"Yang","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.02.024_b0320","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ejmech.2018.11.015","article-title":"Design, synthesis and biological evaluation of novel, orally bioavailable pyrimidine-fused heterocycles as influenza PB2 inhibitors","volume":"162","author":"Xiong","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126639","article-title":"Novel influenza polymerase PB2 inhibitors for the treatment of influenza A infection","volume":"29","author":"Zhang","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.02.024_b0330","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.1021\/jm100888d","article-title":"Aldehyde oxidase: an enzyme of emerging importance in drug discovery","volume":"53","author":"Pryde","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0335","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1021\/acsmedchemlett.6b00487","article-title":"Novel 2-substituted 7-azaindole and 7-azaindazole analogues as potential antiviral agents for the treatment of influenza","volume":"8","author":"Bandarage","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.02.024_b0340","doi-asserted-by":"crossref","first-page":"9680","DOI":"10.1021\/acs.jmedchem.9b01091","article-title":"Design, synthesis and biological evaluation of novel indoles targeting the influenza PB2 cap binding region","volume":"62","author":"McGowan","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0345","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1021\/ja00112a001","article-title":"hydrophobic, non-hydrogen-bonding bases and base pairs in DNA","volume":"117","author":"Schweitzer","year":"1995","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.drudis.2022.02.024_b0350","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1039\/C9CP06303J","article-title":"Combined strategies in structure-based virtual screening","volume":"22","author":"Wang","year":"2020","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.drudis.2022.02.024_b0355","doi-asserted-by":"crossref","first-page":"116515","DOI":"10.1016\/j.bmc.2021.116515","article-title":"Identification of novel influenza polymerase PB2 inhibitors using virtual screening approach and molecular dynamics simulation analysis of active compounds","volume":"52","author":"Xu","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0360","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.3390\/molecules25225291","article-title":"Identification of novel influenza polymerase PB2 inhibitors using a cascade docking virtual screening approach","volume":"25","author":"Zhao","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.02.024_b0365","doi-asserted-by":"crossref","first-page":"6944","DOI":"10.3390\/molecules26226944","article-title":"Virtual screening and molecular simulation study of influenza polymerase PB2 inhibitors","volume":"26","author":"Zong","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.02.024_b0370","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0042-6822(90)90186-U","article-title":"Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983","volume":"175","author":"Rota","year":"1990","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2022.02.024_b0375","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.2105\/AJPH.2012.301137","article-title":"The burden of influenza B: a structured literature review","volume":"103","author":"Paul Glezen","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.drudis.2022.02.024_b0380","doi-asserted-by":"crossref","first-page":"7504","DOI":"10.1128\/JVI.02375-10","article-title":"Recognition of cap structure by influenza B virus RNA polymerase is less dependent on the methyl residue than recognition by influenza A virus polymerase","volume":"85","author":"Wakai","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2022.02.024_b0385","doi-asserted-by":"crossref","first-page":"9141","DOI":"10.1074\/jbc.M115.636464","article-title":"The crystal structure of the PB2 cap-binding domain of influenza B virus reveals a novel cap recognition mechanism","volume":"290","author":"Liu","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0390","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1074\/jbc.M115.693051","article-title":"Molecular basis of mRNA cap recognition by influenza B polymerase PB2 subunit","volume":"291","author":"Xie","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2022.02.024_b0395","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.molcel.2015.11.016","article-title":"Influenza polymerase can adopt an alternative configuration involving a radical repacking of PB2 domains","volume":"61","author":"Thierry","year":"2016","journal-title":"Mol Cell"},{"key":"10.1016\/j.drudis.2022.02.024_b0400","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3390\/v13071196","article-title":"Comprehensive profiling of mutations to influenza virus PB2 that confer resistance to the cap-binding inhibitor pimodivir","volume":"13","author":"Shirleen Soh","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.drudis.2022.02.024_b0405","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/infdis\/jiy547","article-title":"Phase 2b study of pimodivir (JNJ-63623872) as monotherapy or in combination with oseltamivir for treatment of acute uncomplicated seasonal influenza A: TOPAZ trial","author":"Finberg","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.drudis.2022.02.024_b0410","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/molecules26041007","article-title":"Structural and thermodynamic analysis of the resistance development to pimodivir (VX-787), the clinical inhibitor of cap binding to PB2 subunit of influenza A polymerase","volume":"26","author":"Gregor","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.02.024_b0415","doi-asserted-by":"crossref","first-page":"9385","DOI":"10.1038\/s41598-017-09538-x","article-title":"Structural basis for therapeutic inhibition of influenza A polymerase PB2 subunit","volume":"7","author":"Ma","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.02.024_b0420","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1039\/D0CS01084G","article-title":"Medicinal chemistry strategies for discovering antivirals effective against drug-resistance viruses","volume":"50","author":"Ma","year":"2021","journal-title":"Chem Soc Rev"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462200085X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462200085X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:58:17Z","timestamp":1761224297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462200085X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S135964462200085X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.02.024","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}